<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pneumocystis Pneumonia (PCP) - Summary of Information</title>
    <style>
        body {
            font-family: 'Arial', sans-serif;
            background-color: #f4f7fc;
            margin: 0;
            padding: 0;
            color: #333;
        }
        header {
            background-color: #2c3e50;
            color: white;
            padding: 20px;
            text-align: center;
        }
        h1 {
            margin: 0;
            font-size: 2em;
        }
        .container {
            max-width: 900px;
            margin: 40px auto;
            padding: 20px;
            background-color: #fff;
            border-radius: 8px;
            box-shadow: 0 2px 15px rgba(0, 0, 0, 0.1);
        }
        h2 {
            color: #2c3e50;
            font-size: 1.5em;
            margin-top: 20px;
        }
        p {
            font-size: 1.1em;
            line-height: 1.6;
            margin: 10px 0;
        }
        ul {
            padding-left: 20px;
            list-style-type: disc;
            font-size: 1.1em;
        }
        ul li {
            margin-bottom: 10px;
        }
        .highlight {
            background-color: #eaf2f8;
            padding: 5px;
            border-radius: 4px;
        }
        .section {
            margin-top: 40px;
        }
        .section:last-child {
            margin-bottom: 0;
        }
        footer {
            background-color: #2c3e50;
            color: white;
            text-align: center;
            padding: 10px 0;
            position: fixed;
            width: 100%;
            bottom: 0;
        }
    </style>
</head>
<body>

<header>
    <h1>Pneumocystis Pneumonia (PCP) - Summary of Information</h1>
</header>

<div class="container">
    <section class="section">
        <h2>Summary</h2>
        <p>Pneumocystis jirovecii pneumonia (PCP) is an opportunistic fungal lung infection that primarily affects immunocompromised individuals. It is strongly associated with HIV/AIDS but can also occur in patients receiving immunosuppressive therapy, those with malignancies, or individuals with primary immunodeficiency disorders.</p>
    </section>

    <section class="section">
        <h2>Clinical Features – Observable Signs and Symptoms of Disease</h2>
        <ul>
            <li>Progressive dyspnea (shortness of breath)</li>
            <li>Nonproductive cough – a dry cough that does not produce mucus</li>
            <li>Fever</li>
            <li>Hypoxia (low levels of oxygen in body tissues) disproportionate to clinical findings</li>
        </ul>
        <p>Symptoms develop gradually over days to weeks.</p>
    </section>

    <section class="section">
        <h2>Diagnosis</h2>
        <p>Laboratory markers – biochemical or molecular indicators measured using bodily fluids:</p>
        <ul>
            <li><span class="highlight">Elevated β-D-glucan</span> – a fungal cell wall component and polysaccharide</li>
            <li><span class="highlight">Increased lactate dehydrogenase (LDH)</span> – an enzyme found in almost all body tissues</li>
        </ul>
        <p>Imaging (Chest X-ray or CT scan):</p>
        <ul>
            <li>Diffuse bilateral infiltrates (abnormal opacities/lumps seen in both lungs) with a ground-glass appearance</li>
        </ul>
        <p>Definitive diagnosis can be made by detecting <span class="highlight">P. jirovecii</span> in induced sputum, bronchoalveolar lavage (BAL), or lung biopsy via:</p>
        <ul>
            <li>Giemsa, Methenamine silver stain, or Immunofluorescence staining – specialized techniques used to identify organisms</li>
            <li><span class="highlight">PCR testing</span> (Polymerase Chain Reaction) – a highly sensitive and specific molecular technique</li>
        </ul>
    </section>

    <section class="section">
        <h2>Treatment</h2>
        <p><strong>First-line therapy:</strong> Trimethoprim/Sulfamethoxazole (TMP/SMX) (high dose)</p>
        <p><strong>Adjunctive therapy:</strong> Glucocorticoids (if PaO₂ < 70 mmHg or A-a gradient > 35 mmHg)</p>
        <p><strong>Prophylaxis:</strong> Treatment taken to prevent disease is indicated for patients with:</p>
        <ul>
            <li>HIV and CD4 < 200 cells/µL</li>
            <li>Other immunocompromised states (e.g., prolonged corticosteroid use)</li>
        </ul>
        <p>Prophylactic regimen: Low-dose TMP/SMX (preferred)</p>
    </section>

    <section class="section">
        <h2>Additional Treatment Information</h2>
        <p>The most common treatment is <strong>trimethoprim/sulfamethoxazole (TMP/SMX)</strong>, also known as co-trimoxazole. It is given by mouth or through a vein for 3 weeks. TMP/SMX may cause side effects such as rash and fever. Alternative medications are available for patients who cannot take TMP/SMX.</p>
        <p><strong>Note:</strong> Unlike other fungal diseases, PCP is treated with an antibiotic (TMP/SMX), and antifungal medications do not work to treat it.</p>
    </section>
</div>

<footer>
    <p>&copy; 2025 Pneumocystis Pneumonia Information. All rights reserved.</p>
</footer>

</body>
</html>
